OnlineEquityCalls.com

Devangshu Dutta,Consulting Editor at Outlook is of the view that Reliance Industries has support at Rs 1880.

Devangshu Dutta, Consulting Editor at Outlook is of the view that Ranbaxy Laboratories looks extremely weak.

Devangshu Dutta, Consulting Editor at Outlook is of the view that Hindustan Unilever Ltd, HUL and ITC are both looking I would say neutral than positive.

Harish Sharma of Edelweiss Securities is of the view that SBI is looking attractive.

Devangshu Dutta, Consulting Editor at Outlook is of the view that there is fair 15% upside in IT space from slightly longer timeframe of 4-6 months.

Educomp today announced that it has signed an agreement with the Department of State Education Research & Training (DSERT), Government of Karnataka for implementation of Computer aided education in 1571 schools in Karnataka.

Devangshu Dutta, Consulting Editor at Outlook is of the view that Unitech and DLF both seem to be heading for lower lows.

Titan Industries, the jewellery and watches division of the Tata Group, has signed a long-term agreement with Hamilton Sundstrand, a subsidiary of United Technologies Corp of the US, to manufacture high precision components for auxiliary power units, ram air turbine, flap actuator systems, engine control, environmental control systems and electronic engine controls that are deployed in leading commercial aircraft like Boeing, Airbus, Embraer and Dassault Falcon.

Country’s largest drug maker Ranbaxy today said its pharmaceutical products, including the HIV/AIDS drugs, which it produces from two of its plants located in Dewas and Ponta Sahib in the country, are safe and is committed to working with US FDA.

Consumer electronics maker BPL Ltd said on Friday its board has approved preferentially issuing 2.43 mn shares to Deutsche Bank AG and its units.

Shares of pharma major Ranbaxy today plunged over six per cent on the domestic bourses amid reports of US President’s Emergency Plan for AIDS Relief (PEPFAR) suspension of funding for three of its generic HIV/AIDS drugs.

20 Microns Ltd has fixed the issue price of its public offering at the upper price band of Rs 55 per share. The company planned to raise Rs 9 crore from the IPO. The issue was subscribed 4.11 times.